Osaic Holdings’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Osaic Holdings’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-925	Closed	–	–	7706
2022 Q3	$0	Hold	925	–	–	﹤0.01%	7707
2022 Q2	$0	Sell	925 -4,000	-81%	-$2.02K	﹤0.01%	7786
2022 Q1	$3K	Buy	4,925 +83	+2%	+$91	﹤0.01%	6824
2021 Q4	$11K	Buy	4,842 +83	+2%	+$281	﹤0.01%	6221
2021 Q3	$22K	Buy	4,759 +500	+12%	+$2.2K	﹤0.01%	5719
2021 Q2	$19K	Buy	4,259 +3,909	+1,117%	+$19.9K	﹤0.01%	5710
2021 Q1	$3K	Buy	+350	New	+$2.88K	﹤0.01%	6438

Osaic Holdings's LOGC Position: Q4 2022 in Review

Osaic Holdings sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 925 shares.

Osaic Holdings first reported a position in LOGC in Q1 2021 and held it in 7 quarters. The position peaked at $22K in Q3 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Osaic Holdings reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Osaic Holdings sold 925 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
Osaic Holdings first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Osaic Holdings's LogicBio Therapeutics, Inc. Common Stock position peaked at $22K in Q3 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Osaic Holdings's 13F filing for Q4 2022, filed 10 Feb 2023.